Cargando…

SMO mutations confer poor prognosis in malignant pleural mesothelioma

BACKGROUND: Malignant pleural mesothelioma (MPM) is an aggressive tumor but approximately 12% of patients survive more than 3 years. The biological differences underlying better outcomes are not known. Several targeted agents and immunotherapy have been ineffective. Hedgehog (Hh) is one emerging pat...

Descripción completa

Detalles Bibliográficos
Autores principales:	Signorelli, Diego, Proto, Claudia, Botta, Laura, Trama, Annalisa, Tiseo, Marcello, Pasello, Giulia, Lo Russo, Giuseppe, Fabbri, Alessandra, Imbimbo, Martina, Busico, Adele, Prelaj, Arsela, Ferrara, Roberto, Galli, Giulia, De Toma, Alessandro, Tamborini, Elena, Pastorino, Ugo, de Braud, Filippo, Gatta, Gemma, Garassino, Marina Chiara, Ganzinelli, Monica
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	AME Publishing Company 2020
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7653142/ https://www.ncbi.nlm.nih.gov/pubmed/33209614 http://dx.doi.org/10.21037/tlcr-19-425

Ejemplares similares

Novel patterns of progression upon immunotherapy in other thoracic malignancies and uncommon populations
por: Ferrara, Roberto, et al.
Publicado: (2021)

Is There an Interplay between Immune Checkpoint Inhibitors, Thromboprophylactic Treatments and Thromboembolic Events? Mechanisms and Impact in Non-Small Cell Lung Cancer Patients
por: Nichetti, Federico, et al.
Publicado: (2019)

Concomitant EML4-ALK rearrangement and EGFR mutation in non-small cell lung cancer patients: a literature review of 100 cases
por: Lo Russo, Giuseppe, et al.
Publicado: (2017)

Treatment patterns among patients with malignant pleural mesothelioma: An Italian, population‐based nationwide study
por: Trama, Annalisa, et al.
Publicado: (2020)

Beyond First-Line Immunotherapy: Potential Therapeutic Strategies Based on Different Pattern Progressions: Oligo and Systemic Progression
por: Prelaj, Arsela, et al.
Publicado: (2021)

EPSILoN: A Prognostic Score for Immunotherapy in Advanced Non-Small-Cell Lung Cancer: A Validation Cohort
por: Prelaj, Arsela, et al.
Publicado: (2019)

Integrating clinical and biological prognostic biomarkers in patients with advanced NSCLC treated with immunotherapy: the DEMo score system
por: Prelaj, Arsela, et al.
Publicado: (2020)

Circulating CD81-expressing extracellular vesicles as biomarkers of response for immune-checkpoint inhibitors in advanced NSCLC
por: Signorelli, Diego, et al.
Publicado: (2022)

Modulation of peripheral blood immune cells by early use of steroids and its association with clinical outcomes in patients with metastatic non-small cell lung cancer treated with immune checkpoint inhibitors
por: Fucà, Giovanni, et al.
Publicado: (2019)

Machine Learning Using Real-World and Translational Data to Improve Treatment Selection for NSCLC Patients Treated with Immunotherapy
por: Prelaj, Arsela, et al.
Publicado: (2022)

Evaluation of Drug—Drug Interactions in EGFR-Mutated Non-Small-Cell Lung Cancer Patients during Treatment with Tyrosine-Kinase Inhibitors
por: Occhipinti, Mario, et al.
Publicado: (2021)

MicroRNAs for the Diagnosis and Management of Malignant Pleural Mesothelioma: A Literature Review
por: Lo Russo, Giuseppe, et al.
Publicado: (2018)

LKB1 mutations are not associated with the efficacy of first-line and second-line chemotherapy in patients with advanced non-small-cell lung cancer (NSCLC): a post hoc analysis of the TAILOR trial
por: Vernieri, Claudio, et al.
Publicado: (2020)

Case Report: Exceptional Response to Poziotinib in Patient with Metastatic Non-Small Cell Lung Cancer With EGFR Exon 20 Insertion Mutation
por: Prelaj, Arsela, et al.
Publicado: (2022)

Beyond LKB1 Mutations in Non-Small Cell Lung Cancer: Defining LKB1less Phenotype to Optimize Patient Selection and Treatment
por: Borzi, Cristina, et al.
Publicado: (2020)

Real-world data to build explainable trustworthy artificial intelligence models for prediction of immunotherapy efficacy in NSCLC patients
por: Prelaj, Arsela, et al.
Publicado: (2023)

PEOPLE (NCT03447678), a first-line phase II pembrolizumab trial, in negative and low PD-L1 advanced NSCLC: clinical outcomes and association with circulating immune biomarkers
por: Lo Russo, G., et al.
Publicado: (2022)

SMO expression level correlates with overall survival in patients with malignant pleural mesothelioma
por: Zhang, Yi, et al.
Publicado: (2013)

High Expression of SMO and GLI1 Genes with Poor Prognosis in Malignant Mesothelioma
por: Ma, Guan-Ying, et al.
Publicado: (2023)

Immunotherapy in malignant pleural mesothelioma: a review of literature data
por: Menis, Jessica, et al.
Publicado: (2021)

Mutational Profile of Malignant Pleural Mesothelioma (MPM) in the Phase II RAMES Study
por: Pagano, Maria, et al.
Publicado: (2020)

Circulating biomarkers in malignant pleural mesothelioma
por: Viscardi, Giuseppe, et al.
Publicado: (2020)

Metabolic rewiring and redox alterations in malignant pleural mesothelioma
por: Urso, Loredana, et al.
Publicado: (2019)

Liquid Biopsy in Malignant Pleural Mesothelioma: State of the Art, Pitfalls, and Perspectives
por: Cavallari, Ilaria, et al.
Publicado: (2019)

Dual SMO/BRAF Inhibition by Flavonolignans from Silybum marianum †
por: Diukendjieva, Antonia, et al.
Publicado: (2020)

PEOPLE (NTC03447678), a phase II trial to test pembrolizumab as first-line treatment in patients with advanced NSCLC with PD-L1 <50%: a multiomics analysis
por: Lo Russo, Giuseppe, et al.
Publicado: (2023)

STAT3 is required for Smo‐dependent signaling and mediates Smo‐targeted treatment resistance and tumorigenesis in Shh medulloblastoma
por: Yuan, Liangping, et al.
Publicado: (2021)

Radium-223 in patients with metastatic castration-resistant prostate cancer: Efficacy and safety in clinical practice
por: Prelaj, Arsela, et al.
Publicado: (2019)

Synergistic targeting of malignant pleural mesothelioma cells by MDM2 inhibitors and TRAIL agonists
por: Urso, Loredana, et al.
Publicado: (2017)

Circular RNA SMO sponges miR-338-3p to promote the growth of glioma by enhancing the expression of SMO
por: Xiong, Zhiyong, et al.
Publicado: (2019)

Expression of Smo in pancreatic cancer CD44(+)CD24(+)cells and construction of a lentiviral expression vector to silence Smo
por: Cong, Peng, et al.
Publicado: (2018)

A Smo/Gli Multitarget Hedgehog Pathway Inhibitor Impairs Tumor Growth
por: Lospinoso Severini, Ludovica, et al.
Publicado: (2019)

Computed Tomography and Spirometry Can Predict Unresectability in Malignant Pleural Mesothelioma
por: Bellini, Alice, et al.
Publicado: (2021)

Diagnostic Challenges in Epithelioid Pleural Mesothelioma: Case Series with Support from Electron Microscopy
por: Fortarezza, Francesco, et al.
Publicado: (2021)

Non-conventional fotemustine schedule as second-line treatment in recurrent malignant gliomas: Survival across disease and treatment subgroup analysis and review of the literature
por: Prelaj, Arsela, et al.
Publicado: (2019)

CoSMoS: Conserved Sequence Motif Search in the proteome
por: Liu, Xiao I, et al.
Publicado: (2006)

Synthesis and Smo Activity of Some Novel Benzamide Derivatives
por: Ding, Huaiwei, et al.
Publicado: (2017)

Recognizing ion ligand binding sites by SMO algorithm
por: Wang, Shan, et al.
Publicado: (2019)

Relapse Patterns and Tailored Treatment Strategies for Malignant Pleural Mesothelioma Recurrence after Multimodality Therapy
por: Bellini, Alice, et al.
Publicado: (2021)

Management of BRCA Tumour Testing in an Integrated Molecular Tumour Board Multidisciplinary Model
por: Azzollini, Jacopo, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_andikoitmjmc4m55gi6l6ce1vh